Year archive

Duality Biotherapeutics, Inc. — 2026 filings

All 21 regulatory filings released by Duality Biotherapeutics, Inc. (9606) in 2026, sourced directly from the official regulator.

21 Filings

2026 Period

2026 filings (21)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PLAN UNDER THE REPURCHASE MANDATE AND PROPOSED INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD Transaction in Own Shares	2026-05-19	English
INSIDE INFORMATION NOTICE OF EXERCISE OF THE DB-1311/BNT324 COST & PROFIT/LOSS SHARING OPTION Regulatory Filings	2026-05-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-07	English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 29, 2026 Declaration of Voting Results & Voting Rights Announcements	2026-04-29	English
2025 Environmental, Social and Governance Report Environmental & Social Information	2026-04-26	English
2025 Annual Report Annual Report FY 2025	2026-04-26	English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON APRIL 29, 2026 Proxy Solicitation & Information Statement	2026-04-14	English
NOTICE OF THE EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2026-04-14	English
(1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTION; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE; AND ( Proxy Solicitation & Information Statement	2026-04-14	English
(1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE Share Issue/Capital Change	2026-04-13	English
INSIDE INFORMATION BIOLOGICS LICENSE APPLICATION FOR DB-1303/BNT323 FOR UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER IN ADULTS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2026-04-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Regulatory Filings	2026-04-09	English
BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2026-04-09	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 Earnings Release FY 2025	2026-03-23	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2026-03-23	English
(1) RESIGNATION OF EXECUTIVE DIRECTOR; (2) APPOINTMENT OF EXECUTIVE DIRECTOR; (3) APPOINTMENT OF CHIEF FINANCIAL OFFICER; AND (4) CHANGE IN COMPOSITION OF BOARD COMMITTEE Board/Management Information	2026-03-23	English
DATE OF BOARD MEETING Report Publication Announcement	2026-03-11	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Regulatory Filings	2026-03-02	English
INSIDE INFORMATION STUDY RESULTS FROM CORE PRODUCT DB-1311/BNT324 AT ASCO GENITOURINARY CANCERS SYMPOSIUM 2026 Regulatory Filings	2026-02-23	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Regulatory Filings	2026-02-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Share Issue/Capital Change	2026-01-07	English